Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers

Published:2017-09 Issue:4 Volume:63 Page:
ISSN:2724-5985
Container-title:Minerva Gastroenterology
language:
Short-container-title:Minerva Gastroenterol

Author:

Tursi Antonio,Allegretta Leonardo,Chiri Stefania,Della Valle Nicola,Elisei Walter,Forti Giacomo,Lorenzetti Roberto,Mocci Giammarco,Penna Antonio,Pranzo Giuseppe,Ricciardelli Cristina,Picchio Marcello

Publisher

Edizioni Minerva Medica

Subject

Gastroenterology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R08Y2017N04A0313

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

2. Biosimilars in inflammatory bowel disease;Journal of Digestive Diseases;2020-10-18

3. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases;Drugs;2020-01-30

4. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations;Minerva Gastroenterologica e Dietologica;2020-01

5. Position statement on the use of biosimilars in inflammatory bowel disease;Swiss Medical Weekly;2019-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP